Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells
- PMID: 25095541
Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells
Abstract
Following a description of the way studies of human leukocyte antigen (HLA) class I antigen expression by tumor cells have evolved through the years, the literature related to the frequency of defects in HLA class I antigen processing machinery (APM) component expression in various types of malignancies is reviewed. In addition, the clinical significance of defects in HLA class I APM components as well as the underlying molecular mechanisms are described. Lastly, potential strategies to overcome the defects in HLAclass I APM component expression and function are discussed. The information presented indicates a revival of the interest in the characterization of HLA class I APM component expression by tumor cells since these molecules may play an important role in the outcome of immunotherapy with inhibitory checkpoint molecule-specific monoclonal antibodies in patients with malignant disease. Furthermore, they may represent a useful prognostic biomarker to select patients who might benefit from these types of immunotherapy.
Similar articles
-
Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma.Cancer Res. 2007 Jun 1;67(11):5471-8. doi: 10.1158/0008-5472.CAN-06-4735. Cancer Res. 2007. PMID: 17545629
-
Defective HLA class I antigen processing machinery in cancer.Cancer Immunol Immunother. 2018 Jun;67(6):999-1009. doi: 10.1007/s00262-018-2131-2. Epub 2018 Feb 27. Cancer Immunol Immunother. 2018. PMID: 29487978 Free PMC article.
-
Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.Int J Mol Sci. 2020 Oct 2;21(19):7295. doi: 10.3390/ijms21197295. Int J Mol Sci. 2020. PMID: 33023239 Free PMC article. Review.
-
HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.Methods Mol Biol. 2020;2055:325-350. doi: 10.1007/978-1-4939-9773-2_15. Methods Mol Biol. 2020. PMID: 31502159 Review.
-
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.Cancer Res. 2006 Sep 15;66(18):9281-9. doi: 10.1158/0008-5472.CAN-06-0488. Cancer Res. 2006. PMID: 16982773
Cited by
-
Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder.Virchows Arch. 2020 Apr;476(4):535-542. doi: 10.1007/s00428-019-02661-2. Epub 2019 Sep 2. Virchows Arch. 2020. PMID: 31485721 Free PMC article.
-
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Oncoimmunology. 2017 Mar 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017. Oncoimmunology. 2017. PMID: 28405494 Free PMC article.
-
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.Clin Cancer Res. 2016 Jan 15;22(2):470-8. doi: 10.1158/1078-0432.CCR-15-0715. Epub 2015 Sep 15. Clin Cancer Res. 2016. PMID: 26373575 Free PMC article.
-
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.Oncotarget. 2016 Feb 16;7(7):7390-402. doi: 10.18632/oncotarget.7180. Oncotarget. 2016. PMID: 26862729 Free PMC article.
-
Histone Deacetylase Inhibitors as Anticancer Drugs.Int J Mol Sci. 2017 Jul 1;18(7):1414. doi: 10.3390/ijms18071414. Int J Mol Sci. 2017. PMID: 28671573 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
